ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Journal and News Scan
June 3, 2022
Submitted by: Mary Hammon
This study evaluates the incidence and risk factors for postoperative renal failure and relationships between renal failure, shunt type, and outcomes after Norwood.
June 3, 2022
Submitted by: Mary Hammon
This study was conducted to determine the incidence of postoperative conduction disorders and need for pacemaker (PM) implantation after aortic valve replacement (AVR) with the Perceval prosthesis (Livanova, Saluggia, Italy).
May 26, 2022
Submitted by: Aristotle Protopapas
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
May 25, 2022
Submitted by: Amy Fiedler
The authors describe recent innovations as they relate to LVAD technical advances and alternative surgical approaches that have been developed and refined.
May 20, 2022
Submitted by: Wei-Guo Ma
This is a compreshensive review on the experience with use of TEVAR in patients with Marfan syndrome, including durablity, complications, and timing, etc. Drs. Steinmetz and Cosellihe also discussed the role and trend of TEVAR in Marfan paitents with aortic disease.
May 19, 2022
Submitted by: Mary Hammon
Transcatheter aortic valve replacement (TAVR) is not inferior to surgical aortic valve replacement (SAVR) when it comes to all-cause mortality after one year. This is among moderate-risk patients with severe, symptomatic aortic stenosis (AS). According to a new analysis published in JAMA, a close comparison revealed that each treatment option is associated with certain benefits over the other.
May 19, 2022
Submitted by: Mary Hammon
A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a discrepancy in data. This has rekindled concerns about reliance on the landmark trial data in the newest coronary revascularization guidelines. CTSNet recently recently published a webinar on this topic featuring leading CT surgeons around the globe.
May 18, 2022
Submitted by: Aristotle Protopapas
Gripping vignette of a fatal case of renocardiac pathologies. The stills from the (sadly non-contrast) CTA are most interesting.
May 10, 2022
Submitted by: Saurabh Gupta
Meta-analysis of 119 studies (approx 38,000 patients) evaluating outcomes of minimally invasive mitral valve surgery with conventional sternotomy approach.
MMVS was associated with fewer days in hospital (RCT: MD: -2.2 days, 95% CI, [-3.7 to -0.8]; observational: MD: -2.4 days, 95% CI, [-2.7 to -2.1]). Observational studies suggested that MMVS reduced transfusion requirements with fewer units transfused per patient (MD: -1.2; 95% CI, [-1.6 to -0.9]) and fewer patients transfused (RR, 0.7; 95% CI, [0.6-0.7]). Observational data also suggested lower mortality with MMVS (RR, 0.6; 95% CI, [0.5-0.7], p < .001, I2 = 0%), but this was not corroborated by RCT data. The risk of postoperative mitral regurgitation (≥2+ or requiring re-intervention) did not differ between the two groups.
May 10, 2022
Submitted by: Saurabh Gupta
Data from Scientific Registry of Transplant Recipients was modeled over 30 years to evaluate temporal trends, as well as graft survival.
Among 56,488 primary adult heart recipients, we observed 5529 (9.8%) all-cause deaths and 1933 (3.4%) graft failure events within 6 months posttransplant. Prevalence of known recipient risk factors increased over time. Unadjusted modeling demonstrated a significant 30-year improvement in graft survival, averaging 2.6% per year (95% confidence interval, 2.4-2.9; P for trend < .001). After adjusting for population changes the 30-year trend remained significant and graft survival improved on average 3.0% per year (95% confidence interval, 2.6-3.3). Regression modeling identified multiple predictors of graft survival. Modeling 2 additional outcomes of 6-month mortality and 6-month graft failure produced similar results.